Reports on long-term complications resulting from treatment for localized prostate cancer are very inconsistent. In order to estimate the risks of long-term erectile dysfunction, urine symptoms and bowel symptoms following prostatectomy (RP), external conventional or conformal beam radiation (ERT or CRT) and brachytherapy (BRT), 98 papers from the PubMed and Cochrane Clinical Trial databases were selected, reviewed and critically evaluated. The majority of papers were institutionbased retrospective and prospective follow-up studies; only two of these studies measured the risk of developing more than one treatment complication. Due to differences in study designs and populations, it is difficult to directly compare studies and not meaningful to calculate summary estimates. In addition to focusing on randomized clinical trials and well-designed population based studies, future research should adopt standardized methodologies and should measure the risk of developing more than one treatment complication.
Introduction
Both physicians and patients need to understand the risks and benefits of treatment for prostate cancer.
Because of decreased quality of life resulting from treatment-related erectile dysfunction (ED), urinary symptoms and/or bowel symptoms, prostate cancer patients may regret choosing more aggressive management (prostatectomy or radiation) over conservative management (CM), also referred to as watchful waiting. This makes shared (informed) decision-making especially important because patients who are actively involved in the decision making process tend to make more conservative choices.
1,2 More importantly, patients who are actively involved in the decision-making process may be less likely to regret their choices, despite unintended treatment complications. 3 Determining the risk of a complication resulting from prostate cancer treatment, however, is not always straightforward. Many prostate cancer patients have ED and urinary symptoms prior to treatment. Therefore, measurement of risk among patients without significant baseline symptoms is needed in order to estimate the risk resulting from treatment. Many patients under CM will develop ED as a result of aging and medical comorbidities, and urinary symptoms (especially lower obstructive symptoms) as a result of prostatic hyperplasia and/ or cancer progression. Alternatively, baseline obstructive urinary symptoms may improve after radical prostatectomy (RP). 4 Therefore, the relative risk (risk of a complication after treatment divided by the risk under CM) or excess risk (risk of a complication after treatment minus the risk under CM) should be considered whenever possible.
Because the literature is not consistent, a structured literature review was used to identify studies that measured the long-term risks of ED, urinary symptoms and bowel symptoms resulting from three treatment modalities for localized prostate cancer: (1) RP, (2) external conventional and conformal beam radiation (ERT and CRT), and (3) interstitial seed implantation or brachytherapy (BRT). Estimates for the risks of prostate cancer treatment complications were derived, highlighting the risk among patients without significant symptoms at baseline, and the relative risk and/or excess risk compared to CM whenever possible. In addition, we critically evaluated these papers in order to identify issues in patient selection and study design that could result in biased estimates for the risk of developing longterm prostate cancer treatment complications.
Methods
A structured literature review was used to derive estimates for ED, urinary symptoms and bowel symptoms resulting from primary treatment modalities for localized prostate cancer. A PubMed search (English language and human studies only) limited to the last ten years was used to identify papers on treatment complications. Four consecutive searches were run using the following MeSH terms: (1) 'prostatic neoplasm' and 'therapy' and 'complications', (2) 'prostatic neoplasm' and 'prostatectomy' and 'complications', (3) 'prostatic neoplasm' and 'radiation' and 'complications', and (4) 'prostatic neoplasm' and 'quality of life'. Finally, the Cochrane Database was searched from 1994-2004 for clinical trials using the following search terms' 'prostate cancer treatment' and 'complications'. All titles were reviewed and papers that measured the risk of ED, urinary symptoms or bowel symptoms following RP, ERT, CRT or BRT for clinically localized prostate cancer were included in the initial selection. Citations from selected papers were also reviewed to identify additional studies. Studies examining outcomes after a combination of treatments or after adjuvant treatment for advanced disease were not selected. Two authors (VB and VH or GJ) reviewed the selected papers to derive estimates for the risk of ED, urinary and bowel symptoms following treatment. Finally, these studies were also analyzed to identify issues in patient selection and study design that could potentially result in a biased assessment for the risk of developing a treatment complication.
Results
The risks of ED, urinary and bowel symptoms resulting from primary prostate cancer treatment modalities (RP, ERT, CRT and BRT) are summarized in Tables 1-3 . Biases resulting from methodological issues in patient selection and study design are also discussed and summarized in Table 4 . The risk of ED increased from 15% at baseline to 47% among patients randomized to ERT, and from 24% at baseline to 52% among patients randomized to CRT. Institutional-based 30 8-69% (o1 to 2%)
23-67%
(1-35%) 12-59% (o1 to 14%) 3-15% (o1 to 24%) 4, 6, 7, [9] [10] [11] [12] [13] [14] 16, 23, 24, 27, 34, 37, 46, 53, [55] [56] [57] [58] 60, 63, 65, 66, [69] [70] [71] 73, 74 Single surgeon case series 2 24-69% 
Literature review
Initially, 158 studies were selected for review. Of these studies, 60 were excluded for the following reasons: 30 only presented quality of life scores (and not the risk of a treatment complication), nine only measured perioperative complications, nine were duplicate papers, six only measured utility weights for prostate cancer health states, three were based on developing questionnaires, two measured complication rates for combination treatments, and one was a literature review ( Figure 1 ). Of the 98 remaining studies, 65 (or 66%) were published in or after 2000 (Figure 2 ). In total, 70 (71%) were based on patients from tertiary care institutions, 5-74 13 (13%) were population-based studies [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] 87 9 (9%) were based on the patients of a single surgeon, 9, 22, 36, [88] [89] [90] [91] [92] [93] and 5 (5%) were results from randomized trials. [94] [95] [96] [97] [98] Only one out of the five randomized trials compared treatment to CM. 97 This is important to note because the comparison of treatment to CM is necessary in order to estimate the relative or excess risk following treatment. There have not been any large trials comparing RP to ERT, CRT or BRT. One study used a case-control design based on a randomized trial. 99 Erectile dysfunction RP. This overall occurrence of ED has been reported to be as low as 14% in single surgeon case series and over 80% in population and institutional-based studies (Table 1) . Nerve sparing surgery may reduce the risk of ED. 89, 90, 92 The risk after treatment and the relative or excess risk compared to CM is often difficult to estimate because many patients have ED prior to surgery and patients under CM will develop ED because of increasing age, medical comorbidities and cancer progression. 26, 87, 97, 100 For example, in a recent Scandinavian trial (695 men with localized prostate cancer, median follow-up 6.2 years), 80% of patients randomized to RP (not necessarily nerve-sparing) and 45% of patients randomized to CM developed ED (relative risk of 1.8, 95% confidence interval: 1.2-2.8); 97 therefore, the excess risk of ED following RP was 0.35 or 35% (as listed in Table 1 ).
Patient selection. ED is more common in older men 40 and in men who are on certain medications or who have medical illnesses such as coronary artery disease, high blood pressure and/or diabetes. 101 Patients with these risk factors are less likely to regain potency after the trauma of surgery. 36 In general, patients who choose (or are candidates for) RP are generally younger and have fewer comorbidities patients than those who choose ). The majority of studies were institutional based (71%) and published after 1999 (66%). Of the studies published before or during 1999, 8% were randomized trials, 8% population based studies, 79% institutional based studies, and 5% single surgeon case series. Of the studies published after 1999, 3% were randomized trials, 16% population based studies, 71% institutional based studies, and 10% single surgeon case series.
Prostate cancer treatment complications V Bhatnagar et al radiation treatment. Thus, the risk of ED after RP measured in cross-sectional and observational studies may be underestimated. Estimates of ED after RP cannot be directly compared to the ED risk after radiation treatment modalities without accounting for age and comorbidity differences in study populations (Table 4) .
Study design. In addition to accounting for baseline differences, only studies that compare the risk of ED after RP to a comparable group of men under CM can measure the relative or excess risk of ED resulting from surgery. Estimates for complication risks may also vary depending on whether the provider or the patient is queried; patient-reported symptoms tend to be higher and differing methods of inquiry might also lead to variation in risk assessment. The estimated risk of ED also varies within and between studies due to differences in the definition of ED. 56 Although ED is most commonly defined as the inability to maintain an erection firm enough for intercourse, ED varies from full erections to no penile stiffness and generally improves in the first year following surgery. Finally, it should be noted that the majority of studies are from tertiary care institutions; 17, 19, 28, 35, 38, [40] [41] [42] 44, 51 several studies are also based on patients who were operated on by a single surgeon. 22, 36, [88] [89] [90] [91] [92] [93] This is important to note because results from high-volume hospitals and/or single surgeons are not always reproducible in community (or population-based) studies (Table 4) .
ERT CRT and BRT. Following radiation, ED results from vascular damage secondary to radiation (as opposed to direct trauma from surgery). As a result, ED generally worsens with time because of radiationinduced scarring 32, 45 but may be more likely (than ED after RP) to respond to treatment with sildenafil (and other phosphodiesterase inhibitors). 61, 102 The risk following radiation treatments also depends upon the radiation dose and how the radiation is delivered. CRT for example, limits radiation damage to surrounding tissues compared to conventional ERT. 95, 103 Brachytherapy (BRT) with Iodine-125 (I125) or Palladium-103 (Pd103) radiation appears to be about as effective as ERT but further minimizes radiation damage to surrounding tissue.
The overall occurrence ED following radiation treatment modalities appears to be less than the risk following RP (Table 1) . 44 Based on a small-randomized trial (98 patients, at least 2 years of follow-up), 47 and 52% of men randomized to ERT and CRT, respectively, had ED; for comparison, only 15 and 24% of men randomized to ERT and CRT had ED at baseline. 94 In a secondary analysis of another randomized trial (415 patients, median follow-up 42 months), approximately 40% of patients had decreased or lost potency after ERT. 84 However, the relative and/or excess risk after treatment cannot be measured because these trials did not follow patients under CM; therefore, the relative and excess risk following treatment is likely to be smaller. The risk of ED after BRT appears to be similar to the risk after CRT (Table 1) . 31 Patient selection and study design. Explanations for discrepancies in reported risks of ED after radiation treatments are similar to the issues discussed previously for RP. Patient selection is important because patients who choose radiation are generally older and have more comorbid illnesses, particularly vascular disease. 104 Thus, it is not possible to directly compare the risk of ED following radiation treatments to the risk following RP based on cross-sectional and observational studies without adjusting for baseline study population differences. In the study design and analysis, it is also important to measure and adjust for the effects of pretreatment potency, as well as the risk of developing ED under CM. Finally, the estimated risk also depends upon the definition used for ED, tends to increase in the years following treatment, and depends upon whether patients or providers are queried (Table 4) .
Urinary symptoms RP. Urinary symptoms after surgery may be mild (some urinary leakage, the use of pads, dribbling, etc.) or severe (frank urinary incontinence, the use of clamps or other devices to hold in urine, etc.). Continence may be more likely to be preserved with nerve-sparing surgery, 37 with preservation of the bladder neck 11 and upon preserving the distal urethral sphincter. 105 Mild urinary symptoms are relatively common following RP ( Table 2 ). The Scandinavian trial mentioned above suggested that the excess risk after RP is about 0.30 or 30%: 50% of men randomized to RP and 20% of men randomized to CM developed urinary leakage at least once a week (relative risk 2.3, 95% confidence interval 1.6-3.2). 97 More severe urinary symptoms after RP are probably rare (Table 2) .
Patient selection and study design. Age appears to be a strong predictor of continence after surgery: the risk is about 5% in men under the age of 70 years and about 10% in men over the age of 70 years. 105, 106 Urinary symptoms also tend to improve with time 11, 12, 38, 63 and the time to regain continence is longer in older men and in men with other comorbid illnesses. 63 Because many patients will also have obstructive symptoms and/or leakage at baseline, 87 symptoms prior to treatment need to be measured and accounted for in the study design and analysis. Patients with baseline lower obstructive symptoms prior to surgery may actually have decreased symptoms following surgery. 4 In addition, patients under CM may develop worsening obstructive urinary symptoms as a result of prostatic hyperplasia and/or cancer progression. 97 Definitions of urinary symptoms vary within and between studies, and results also depend partially on whether providers or patients are queried. Urinary complications appear to be reduced if the surgery is performed in high-volume hospitals 106 and/or by experienced surgeons 107 (Table 4) .
ERT CRT and BRT. Many men will experience mild irritative urinary symptoms after radiation treatment for prostate cancer (less than or equal to Radiation Treatment Oncology Group or RTOG grade 2, some dribbling, frequency or urgency). Total urinary incontinence and other severe symptoms (greater than RTOG grade 2) are probably rare 5, 13, 18, 42 (Table 2) . Urinary symptoms postradiation may also be related to dose 21 and may be higher with BRT compared to ERT or CRT. 70 As mentioned previously, many men under CM will also Table 2 ).
99
Patient selection and study design. Patients who chose radiation treatment are generally older than patients who choose (or are not candidates for) RP; both the risk of developing urinary symptoms after treatment and the risk of baseline symptoms prior to treatment (especially obstructive symptoms) increase with age. Because of this, the risk following ERT or CRT from descriptive and observational studies cannot be directly compared to the risk following RP without adjusting for the effects of age and comorbidities. Pretreatment symptoms and posttreatment risks of those under CM also need to be accounted for in order to accurately assess the risk resulting from radiation treatment. Symptoms are also described differently both within and between studies and standardized definitions, such as the RTOG grading for urine and bowel symptoms, facilitate the comparison of estimates between studies (Table 4) .
Bowel symptoms ERT, CRT and BRT. Chronic bowel symptoms usually result from radiation treatment modalities. Mild symptoms are common following ERT (less than or equal to RTOG Grade 2, frequent bowel movements and/or occasional cramping) ( Table 3 ). Based on a randomized trial, the overall risk of Grade 1 and Grade 2 rectal toxicity after ERT was 47 and 10%, respectively (the total risk of mild symptoms was 57% as shown in Table 3 ); the risk after CRT was slightly lower (40 and 7%, respectively, total risk of mild symptoms 47% as shown in Table 3 ). 98 However, more severe symptoms (over RTOG grade 2, stool incontinence, rectal bleeding and/or perforation) may also occur in up to approximately 40% of patients following ERT or CRT (Table 3) . After BRT, the risk of mild bowel symptoms is generally less than 20% in the first year of treatment; more severe long-term bowel symptoms are also probably not common. 31, 34, 67, 78 Patient selection and study design. In the absence of treatment, problems with bowel functioning are not as common as problems with ED and urinary symptoms in older men. Thus, the risk of developing bowel symptoms as a result of treatment is not as prone to bias resulting from patient selection. The risk of bowel symptoms, however, may be higher in patient reported (as opposed to provider-reported) studies. Not all studies use standard definitions for bowel symptoms (such as the RTOG grading) and the risk of bowel symptoms will depend upon the description of symptoms (Table 3) . Bowel complications such as rectal bleeding and fistula may also develop several years after ERT or CRT, necessitating long follow-up periods in order to accurately measure the long-term risks (Table 4) . 108 
Discussion
Estimates of the risk for developing complications resulting from primary prostate cancer treatment modalities vary considerably. A recent randomized trial showed that the excess risk of ED after RP is around 0.35 or 35%. 97 This risk will increase with age and comorbid illnesses, and is attenuated by nerve-sparing surgery. The risk of ED following radiation treatment modalities appears to be less than the risk following RP; the magnitude of the difference is unclear because only a rough comparison is possible based on the current literature. The incidence of ED, however, increases in the years following radiation as a result of scarring. Compared to ERT, both CRT and BRT attenuate the risk of ED, and radiation-induced ED is more likely to respond to pharmacological treatment.
Urinary symptoms following RP are usually mild; based on a recent randomized trial, the excess risk following RP (compared to CM) is about 0.30 or 30%. 97 As with ED, this risk is higher in older men and may also be attenuated by nerve-sparing surgery and other new surgical approaches. The risk of mild irritative urinary symptoms following ERT is similar to the risk of urinary symptoms following RP, although, as mentioned above, only a rough comparison is possible. While CRT decreases this risk, BRT may increase this risk.
Finally, after ERT or CRT up to approximately 60 and 50% of patients, respectively, may experience mild bowel symptoms. Up to about 25 and 40% of patients may experience more severe symptoms after ERT and CRT, respectively. Bowel symptoms may also develop several years after treatment. The risk of mild bowel symptoms appear to be less than less than 20% following BRT.
It remains difficult for health care providers and researchers to confidently estimate the risks of ED, urinary and bowel symptoms following prostate cancer treatment based on the current literature. Thus, the second purpose of this paper was to critically appraise the literature and identify sources of bias that make these studies difficult to interpret; these are summarized in Table 4 . Only five randomized trials were identified and other search strategies or the use of other databases (other than PubMed and the Cochrane Database) may have yielded additional clinical trials for review. Results from randomized trails, however, cannot always be generalized to the majority of patients treated in the community because randomized trials are based on carefully selected patients treated in specialized centers. Conducting trials comparing primary prostate cancer treatment modalities is also difficult because older patients may not be surgical candidates and younger patients may not want to confront the risk of radiation induced bowel symptoms (thus, it may be difficult to find patients of similar age who would be willing to be randomized to either surgery or radiation). As discussed, trials comparing treatment to CM are also important because patients under CM are also prone to develop ED and obstructive urinary symptoms because of aging, medical comorbidities, prostatic hyperplasia and/or cancer progression. 12, 97 While one trial comparing treatment (RP) to CM was identified in this review, 97 the majority of men in this trial were not diagnosed by PSA screening. Patients who are diagnosed by screening are generally younger and are more likely to be candidates for nerve sparing surgery because of localized disease. Therefore, patients in the post-PSA era may be less likely to develop Prostate cancer treatment complications V Bhatnagar et al treatment complications. Only a subset of men from the original trial completed the quality of life assessment and the extent to which this missing data biases the observed complication risks is unclear. These men were also surveyed only at one time point so quality of life changes over time could not be assessed. In order to more accurately evaluate outcomes, patients need to be followed for many years (especially under CM and after radiation therapies) because ED, urinary symptoms and bowel symptoms (after radiation therapies) may worsen over time.
A large randomized trial based on men who have been diagnosed by PSA screening is currently underway, but results will not be available for several years. 109 The long natural history of prostate cancer also necessitates long follow up times in order to detect survival differences. 110 Loss to follow-up may become problematic and cross over between treatment arms may contaminate the results; this later issue is more likely to occur in patients randomized to CM because some patients may decide to undergo more aggressive treatment (RP or radiation) during the course of follow-up. Several studies have suggested better disease-free survival after RP or radiation treatments for localized prostate cancer 97, [111] [112] [113] [114] [115] and a recent follow-up of the Scandinavian trial found increased survival among men randomized to prostatectomy. 116 Probably as a result of these difficulties, the majority of studies found for review were institutional-based or single surgeon case series. Similar to randomized trials, however, results from tertiary hospitals and specialized surgeons are not always reproducible in the community setting because of patient selection and technical expertise. These studies are also especially prone to publication bias because institutions and surgeons with less than optimal outcomes are probably less likely to publish their results. Well-designed population based studies that query patients and control for pretreatment symptoms, age and co-morbidities are needed in order to understand long-term outcomes for men after different treatment modalities (including CM) in the post-PSA screening era. 117 The majority of population based studies have been published after 1999 and examples of these databases include: Medicare, 18, 77, 78 Surveillance Epidemiology and End Results (SEER), 77, 83 the Prostate Cancer Outcomes Study (PCOS), 81, 82, 118 Cancer of the Prostate Strategic Urologic Research and Endeavor (CaPSURE). 79, 119 Finally, when choosing among treatment options, it is also important to consider the quality of life effects of a complication. 120 Several standardized measures for health related quality of life are widely utilized and include: SF-36, 18, 29, 41, 71, 73, 79, 119 the UCLA Prostate Cancer Index, 18, 29, 41, 71, 73 the AUA Symptom Score, 54, 63 the Functional Assessment of Cancer Therapy, 71,121 the EORTC questionnaire 14, 122 and the ICS Male Questionnaire. 22 Another commonly used metric for the impact of a treatment complication on quality of life is a utility weight. While a discussion of this literature is beyond the scope of this review, [123] [124] [125] [126] [127] [128] [129] [130] [131] utility weights are mentioned here because our previous work suggested that the disutility associated with multiple symptoms was higher than the disutility associated with a single symptom. 131 While this was not surprising, the relationship between utility weights and number of symptoms was neither additive nor multiplicative; therefore, individual preferences need to be considered because there does not seem to be a straightforward way to infer the impact of multiple symptoms on an individual's quality of life. More importantly, many men will probably have more than one treatment complication as a result of prostate cancer or prostate cancer treatment and we only identified two studies that measured the risk of developing multiple treatment complications. 16, 88 In this sense, the current literature may seriously under estimate the impact of treatment on quality of life because the risk of multiple treatment complications are generally not measured.
Conclusions
Clinicians and health care providers need to provide unbiased estimates of the risks associated with prostate cancer treatment in order to facilitate patient decisionmaking. We have examined the range of post-treatment complication risks reported in the literature (Tables 1-3) and highlighted estimates most likely to reflect risks following RP, ERT, CRT and BRT. After being presented with information about the chances of treatment complications, patients should explore their own values in order to choose an option that best matches their preferences.
Determining more accurate estimates for complication risks is difficult because many studies reviewed were biased by patient selection and inconsistencies in study design. This review highlights some of the biases that should be considered when interpreting or designing similar studies ( Table 4 ) and suggests that further research needs to measure the risk of developing more than one treatment complication. Long-term monitoring of previously treated prostate cancer patients, especially for bowel symptoms in patients who have had radiation, is also important because treatment complications may develop several years after primary treatment. Randomized trials generally reduce most sources of bias and it is reassuring that trials are increasingly measuring treatment complications. 97 We anticipate outcomes from randomized trials in the post-PSA era in the near future. 109 However, randomized trials cannot always be generalized to other patients; therefore, population based studies are also important because they are usually based on patients treated in the community setting. The maturation of several population-based databases discussed above is expected in the next several years; 117 this should result in more accurate measurements of longterm treatment outcomes in the post-PSA era. Prostate cancer treatment complications V Bhatnagar et al
